Skip to main content
. Author manuscript; available in PMC: 2009 Aug 17.
Published in final edited form as: Immunity. 2008 Jul 18;29(1):150–164. doi: 10.1016/j.immuni.2008.05.012

Figure 3. SLE transcriptional vectors.

Figure 3

A) Composite transcriptional vectors identified from a pediatric SLE patient population sampled prior to the initiation of therapy. Each line on the radar plot represents a patient profile (logarithmic scale). Values are normalized per-gene using the median expression value of healthy. The thicker line represents the average normalized expression profile for this group of patients. Profiles generated for healthy volunteers B) and an independent cohort of pediatric SLE patients under treatment C). Averaged normalized expression profiles for treated (green) and untreated (orange) SLE patients cohorts D). Patient profiles were plotted on the same vectors on the basis of clinical activity (SLEDAI), regardless of treatment. E) Patients with low disease activity (SLEDAI from 0 to 6). F) Patients with high disease activity (SLEDAI from 14 to 28).